Cardiovascular therapies and risk for development of diabetes

J Am Coll Cardiol. 2004 Aug 4;44(3):509-12. doi: 10.1016/j.jacc.2004.03.071.


The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials have suggested a difference in the emergence of new diabetes according to cardiovascular medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development than beta-blockers and diuretics. Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Calcium Channel Blockers / administration & dosage
  • Cardiovascular Agents / administration & dosage*
  • Cardiovascular Agents / adverse effects*
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / prevention & control*
  • Diuretics / adverse effects
  • Humans
  • Incidence
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • United States / epidemiology


  • Adrenergic beta-Antagonists
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Cardiovascular Agents
  • Diuretics